Tumor	B-Cancer
Angiogenesis	O
:	O
Initiation	O
and	O
Targeting	O
-	O
Therapeutic	O
Targeting	O
of	O
an	O
FGF	O
-	O
Binding	O
Protein	O
,	O
an	O
Angiogenic	O
Switch	O
Molecule	O
,	O
and	O
Indicator	O
of	O
Early	O
Stages	O
of	O
Gastrointestinal	B-Cancer
Adenocarcinomas	I-Cancer
-	O
.	O

Tumor	B-Cancer
angiogenesis	O
has	O
been	O
related	O
to	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
toward	O
more	O
aggressive	O
behavior	O
of	O
human	O
tumors	B-Cancer
.	O

In	O
particular	O
,	O
the	O
activity	O
of	O
angiogenic	O
factors	O
is	O
crucial	O
for	O
tumor	B-Cancer
progression	O
.	O

We	O
previously	O
characterized	O
a	O
secreted	O
fibroblast	O
growth	O
factor	O
-	O
binding	O
protein	O
(	O
FGF	O
-	O
BP	O
)	O
as	O
a	O
chaperone	O
molecule	O
,	O
which	O
binds	O
to	O
various	O
FGFs	O
,	O
enhances	O
FGF	O
-	O
mediated	O
biochemical	O
and	O
biologic	O
events	O
and	O
importantly	O
is	O
a	O
crucial	O
rate	O
-	O
limiting	O
factor	O
for	O
tumor	B-Cancer
-	O
dependent	O
angiogenesis	O
.	O

We	O
generated	O
monoclonal	O
antibodies	O
that	O
target	O
FGF	O
-	O
BP	O
protein	O
and	O
used	O
them	O
as	O
a	O
tool	O
to	O
evaluate	O
frequency	O
and	O
pattern	O
of	O
FGF	O
-	O
BP	O
expression	O
during	O
the	O
malignant	O
progression	O
of	O
pancreas	B-Cancer
and	O
colorectal	B-Cancer
carcinoma	I-Cancer
in	O
archival	O
tissue	B-Tissue
samples	I-Tissue
.	O

We	O
found	O
that	O
FGF	O
-	O
BP	O
is	O
dramatically	O
upregulated	O
during	O
the	O
initiation	O
of	O
colorectal	B-Cancer
and	O
pancreatic	B-Cancer
adenocarcinoma	I-Cancer
.	O

Crucial	O
genetic	O
events	O
underlying	O
the	O
initiation	O
and	O
progression	O
of	O
colorectal	B-Cancer
and	O
pancreatic	B-Cancer
adenocarcinoma	I-Cancer
with	O
a	O
particular	O
focus	O
on	O
the	O
modulation	O
of	O
angiogenesis	O
and	O
antiangiogenic	O
therapies	O
are	O
discussed	O
.	O

We	O
propose	O
that	O
the	O
upregulation	O
of	O
the	O
secreted	O
FGF	O
-	O
BP	O
protein	O
during	O
early	O
phases	O
of	O
pancreas	B-Cancer
and	O
colon	B-Cancer
cancer	I-Cancer
could	O
make	O
this	O
protein	O
a	O
possible	O
serum	B-Organism_substance
marker	O
indicating	O
the	O
presence	O
of	O
high	O
-	O
risk	O
premalignant	B-Pathological_formation
lesions	I-Pathological_formation
.	O

Furthermore	O
,	O
the	O
biological	O
activity	O
of	O
FGF	O
-	O
BP	O
is	O
neutralized	O
by	O
monoclonal	O
antibodies	O
suggesting	O
the	O
potential	O
for	O
antibody	O
-	O
based	O
therapeutic	O
targeting	O
.	O

